Chardan Capital Markets cuts Alnylam Pharmaceuticals price target to $375 from $425
ALNY•Chardan Capital Markets cut its price target for Alnylam Pharmaceuticals to $375 from $425.
Related News
Tech rout hits South Korea, Taiwan; Jakarta faces worst month in 18 years
SPY•
JP Morgan raises Kymera Therapeutics target price to $141 from $140
KYMR•
Macquarie cuts MGM Resorts International target price to $46 from $48
MGM•
Alnylam Pharmaceuticals: TD Cowen cuts target price to $354 from $482
ALNY•
FedEx: Stephens raises target price to $360 from $346
FDX•